A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Sarosiek, Shayna, Flynn, Catherine A., Leventoff, Carly, Little, Megan, White, Timothy, Meid, Kirsten, Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421949/
https://www.ncbi.nlm.nih.gov/pubmed/36051045
http://dx.doi.org/10.1002/jha2.493
_version_ 1784777708902809600
author Castillo, Jorge J.
Sarosiek, Shayna
Flynn, Catherine A.
Leventoff, Carly
Little, Megan
White, Timothy
Meid, Kirsten
Treon, Steven P.
author_facet Castillo, Jorge J.
Sarosiek, Shayna
Flynn, Catherine A.
Leventoff, Carly
Little, Megan
White, Timothy
Meid, Kirsten
Treon, Steven P.
author_sort Castillo, Jorge J.
collection PubMed
description The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four‐week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib.
format Online
Article
Text
id pubmed-9421949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94219492022-08-31 A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib Castillo, Jorge J. Sarosiek, Shayna Flynn, Catherine A. Leventoff, Carly Little, Megan White, Timothy Meid, Kirsten Treon, Steven P. EJHaem Short Reports The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four‐week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib. John Wiley and Sons Inc. 2022-06-07 /pmc/articles/PMC9421949/ /pubmed/36051045 http://dx.doi.org/10.1002/jha2.493 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Castillo, Jorge J.
Sarosiek, Shayna
Flynn, Catherine A.
Leventoff, Carly
Little, Megan
White, Timothy
Meid, Kirsten
Treon, Steven P.
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title_full A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title_fullStr A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title_full_unstemmed A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title_short A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
title_sort pilot study on dasatinib in patients with waldenström macroglobulinemia progressing on ibrutinib
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421949/
https://www.ncbi.nlm.nih.gov/pubmed/36051045
http://dx.doi.org/10.1002/jha2.493
work_keys_str_mv AT castillojorgej apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT sarosiekshayna apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT flynncatherinea apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT leventoffcarly apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT littlemegan apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT whitetimothy apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT meidkirsten apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT treonstevenp apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT castillojorgej pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT sarosiekshayna pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT flynncatherinea pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT leventoffcarly pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT littlemegan pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT whitetimothy pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT meidkirsten pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib
AT treonstevenp pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib

Ejemplares similares